Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ONCY
Strong SellSinkerOncolytics Biotech Inc. · Healthcare · United States · $109M · Avg Vol: $612K/d
COMPANY DESCRIPTION
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on the development of pelareorep, an oncolytic virus designed to induce an anti-cancer immune response. The company's unique competitive position lies in leveraging its proprietary virus to treat multiple cancer types in combination with other therapies, aiming to improve patient outcomes through an immunotherapeutic approach.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.32 | -0.31 | -0.29 | -0.30 | — | -0.35 | -0.38 | -0.34 | — |
| Shares | 61.3M | 74.4M | 80.0M | 108.0M | +76.1% | 127.5M | — | — | — |
| Debt | 0.3M | 0.3M | 0.8M | 0.6M | 27.0% | 0.4M | — | — | — |
| Equity | 19.5M | 20.8M | 3.3M | -3.8M | -58.9% | — | — | — | — |
| Op CF | -17.2M | -21.4M | -19.9M | -20.1M | — | -26.7M | — | — | — |
| Inv CF | -15.0M | 15.2M | -0.2M | -6.0K | — | — | — | — | — |
| Fin CF | 9.0M | 24.1M | 5.0M | 14.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ONCY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ONCY | Oncolytics Biotech Inc.(you) | $109M | 5 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| GNLX | Genelux Corporation | $120M | 4 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 7 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%